PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: StockInterview.com

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

On the Horizon - Pheromone Sciences Commercializing the ‘Reversal of Diabetes’ - Research being conducted at the University of Western Ontario by a world-renown immunologist may help bring about the commercialization of a surgical procedure for patients with Type 1 diabetics.
On the Horizon - Pheromone Sciences Commercializing the ‘Reversal of Diabetes’

 

NewswireToday - /newswire/ - Sarasota, FL, United States, 2006/08/24 - Research being conducted at the University of Western Ontario by a world-renown immunologist may help bring about the commercialization of a surgical procedure for patients with Type 1 diabetics..

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Current diabetic research being conducted by Pheromone Sciences (TSX:PHS) may build upon the University of Minnesota’s success in reversing diabetes in monkeys with islet cell transplants derived from the pancreas of pigs. One of the problems with the Minnesota animal experiments were the use of a cocktail of immunosuppression drugs to help the immune systems of monkeys accept the islet cells from pig pancreas.

Dr. David White, chairman of the scientific advisory board for Pheromone Science Corp and Novartis/Stiller Professor of Xenotransplantation at the University of Western Ontario, told StockInterview.com, “When it comes to animal-to human transplants, the amount of immunosuppressive drugs that you have to give to stop this rejection is dangerous to the patient.” White told StockInterview, “We’ve been looking for a way to transplant these islets without having to give these dangerous drugs.”

The world-renown immunologist’s procedure would inject a combination of Sertoli cells and islet cells from pigs into the Type 1 diabetic patient to eliminate the necessity of immunosuppression drugs and to prevent the body’s rejection of the transplanted cells. The use of Sertoli cells would facilitate acceptance of the pig islet cells by the human body’s immune system.” We’re actually in the curious situation that we already have the clinical trials done, and now we’re working on the pre-clinical studies,” Dr. White told StockInterview.

About Stockinterview.com

For the entire interview with Dr. David White, please visit our website.

Stockinterview.com is a rapidly growing online news service, which provides investigative reporting, editorial, analysis and commentary of the nuclear fuel cycle, uranium mining, nuclear power, the environment and the natural resource industry. Over the past three years, the Internet news website has covered the nuclear energy renaissance, the worldwide uranium mining boom and the potential influence of alternative fuel sources on China’s dramatic economic growth.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: StockInterview.com

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


On the Horizon - Pheromone Sciences Commercializing the ‘Reversal of Diabetes’

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Julie Ickes 
941-929-1640 editor[.]stockinterview.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any StockInterview.com securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From StockInterview.com / Company Profile


Read Health/Surgery Most Recent Related Newswires:

USACS Announces New Integrated Acute Care Partnership with Sharon Regional Health System
Frost & Sullivan Highlights STANLEY Healthcare's Design Innovation and Leadership in Addressing the Changing Needs of the Senior Living Industry
USACS Additional Integrated Acute Care Partnership with MetroSouth Medical Center
Big Data Analytics to Disrupt U.S. Next-generation Sequencing Informatics Market with Double-digit Growth
Bionic Prosthetics Manufacturers Drive R&D Initiatives across Emerging Markets to Impel its Adoption
Frost & Sullivan Acclaims CGI’s Advanced Genomic & Biomarker Technologies That Drive Industry Innovation in Support of Precision Cancer Treatment
Frost & Sullivan Honors Linguamatics for Developing a Best-in-Class NLP-based Data Mining Platform for the Healthcare Industry
Therapist Launches Podcast to Reach Larger Audience
Top Innovative Health and Wellness Technologies to Accelerate Global Adoption of Precision Medicine Finds Frost & Sullivan
Rheumatoid Arthritis Diagnosis Tests Market Size to Expand At 6.2% CAGR through 2022 Says PMR
Persistence Market Research Publishes Health Information Exchange Market Opportunities and Forecasts 2017-2025
Persistence Market Research Publishes Microtome Cryostat Equipment Market Opportunities and Forecasts, 2017-2025
North America to Account for 4.3% CAGR in Global Hip Replacement Market Reports Persistence Market Research
HPMC Capsules Market to Register 10.9% CAGR During 2017-2025 Finds Persistence Market Research
Persistence Market Research Publishes Blood Thinner Market Opportunities and Forecasts 2017-2025

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)